A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses - An imaging-based study with controls

East Asian Archives of Psychiatry

Volumn 21, Issue 1, 2011, Pages 10-16

  Joseph, Anup Mathew ^a   Venkatasubramanian, Ganesan ^b   Sharma, Podila Satya Venkata Narasimha ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Diabetes mellitus; Dyslipidemias; Insulin resistance; Intra abdominal fat; Subcutaneous fat; Weight gain

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; OLANZAPINE;

ABDOMINAL FAT; ARTICLE; BODY MASS; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTRAABDOMINAL FAT; METABOLIC PARAMETERS; PSYCHOANALYSIS; PSYCHOSEXUAL DEVELOPMENT; PSYCHOSIS; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; INTRA-ABDOMINAL FAT; LIPIDS; LONGITUDINAL STUDIES; MIDDLE AGED; PSYCHOTIC DISORDERS; TOMOGRAPHY, X-RAY COMPUTED; WAIST CIRCUMFERENCE; WAIST-HIP RATIO; YOUNG ADULT;

EID: 79953826716     PISSN: 20789947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91.
2. Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009;70:487-99.
3. Sacks FM. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry 2004;65 Suppl 18:S3-12.
4. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44. (Pubitemid 29036692)
5. Viswanathan V. Type 2 diabetes and diabetic nephropathy in India - magnitude of the problem. Nephrol Dial Transplant 1999;14:2805-7.
6. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-60. (Pubitemid 350069735)
7. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985;10:141-6.
8. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 1983;7:437-45. (Pubitemid 13020976)
9. Sjöström L, Kvist H, Cederblad A, Tylén U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986;250:E736-45.
10. Kvist H, Chowdhury B, Sjöström L, Tylén U, Cederblad A. Adipose tissue volume determination in males by computed tomography and 40K. Int J Obes 1988;12:249-66.
11. Al-Attar SA, Pollex RL, Robinson JF, Miskie BA, Walcarius R, Rutt BK, et al. Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Med Imaging 2006;6:11.
12. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41. (Pubitemid 34098681)
13. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999-2008. (Pubitemid 38210353)
14. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62. (Pubitemid 38085215)
15. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004;65 Suppl 18:S27-35.
16. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96. (Pubitemid 29517559)
17. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65 Suppl 18:S36-46.
18. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-32. (Pubitemid 30365564)
19. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005;162:118-23. (Pubitemid 40095680)
20. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003;64:1436-9. (Pubitemid 41270101)
21. Guha P, Roy K, Sanyal D, Dasgupta T, Bhattacharya K. Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics. J Indian Med Assoc 2005;103:660-4. (Pubitemid 43822137)
22. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
23. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6. (Pubitemid 41110454)
24. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry 2009;70:318-25.
25. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62 Suppl 27:S27-34.
26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. (Pubitemid 41345943)
27. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100. (Pubitemid 32199865)
28. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62 Suppl 7:S22-31.
29. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997;273:E425-32.
30. Ohlson LO, Larsson B, Svärdsudd K, Welin L, Eriksson H, Wilhelmsen L, et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055-8.
31. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-71. (Pubitemid 40322092)